Show
Sort by
-
Residual cardiovascular risk is tracked by apolipoprotein B in coronary patients with elevated serum triglyceride levels: the ESC EORP EUROASPIRE IV survey
-
Prevalence and prognostic importance of chronic kidney disease in patients with coronary heart disease: results from the combined EUROASPIRE IV and V studies
-
Physician perspectives on Lp(a) testing and management in patients with cardiovascular disease: interviews from seven countries across five world health organization regions from INTERASPIRE
-
Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regions
-
Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO regions : results from INTERASPIRE
-
International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study
-
Anxiety and depression and secondary prevention of coronary heart disease in 14 countries across six WHO regions: the INTERASPIRE study
-
Global detection and management of dysglycaemic patients with coronary artery disease results from the INTERASPIRE survey from 14 countries across six WHO regions
-
Cardiac Rehabilitation in Patients with Coronary Heart Disease – Provision, Attendance, and Outcomes: Results from the INTERASPIRE Survey from Fourteen Countries Across Six WHO Regions
-
Global variation in lipoprotein(a) levels among patients with coronary heart disease : insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies